Diallyl Biphenyl-Type Neolignans Have a Pharmacophore of PPARα/γ Dual Modulators
10.4062/biomolther.2019.180
- Author:
Yujia HAN
1
;
Jingjing LIU
;
Sungjin AHN
;
Seungchan AN
;
Hyejin KO
;
Jeayoung C. SHIN
;
Sun Hee JIN
;
Min Won KI
;
So Hun LEE
;
Kang Hyuk LEE
;
Song Seok SHIN
;
Won Jun CHOI
;
Minsoo NOH
Author Information
1. College of Pharmacy and Natural Products Research Institute, Seoul National University, Seoul 08826, Republic of Korea
- Publication Type:Original Article
- From:Biomolecules & Therapeutics
2020;28(5):397-404
- CountryRepublic of Korea
- Language:0
-
Abstract:
Adiponectin secretion-promoting compounds have therapeutic potentials in human metabolic diseases. Diallyl biphenyl-type neolignan compounds, magnolol, honokiol, and 4-O-methylhonokiol, from a Magnolia officinalis extract were screened as adiponectin-secretion promoting compounds in the adipogenic differentiation model of human bone marrow mesenchymal stem cells (hBM-MSCs). In a target identification study, magnolol, honokiol, and 4-O-methylhonokiol were elucidated as PPARα and PPARγ dual modulators. Diallyl biphenyl-type neolignans affected the transcription of lipid metabolism-associated genes in a different way compared to those of specific PPAR ligands. The diallyl biphenyl-type neolignan structure provides a novel pharmacophore of PPARα/γ dual modulators, which may have unique therapeutic potentials in diverse metabolic diseases.
